1. Home
  2. /Report-store
  3. /Life Sciences
  4. /Diagnostics and Biotech
Report image for Blood Screening Market Size, Share, Trends & Global Forecast 2026–2035

Blood Screening Market Size, Share, Trends & Global Forecast 2026–2035

The Blood Screening Market is Segmented By Product & Service (Reagents & Kits (NAT Reagents & Kits, Enzymes & Polymerases, Standards & Controls, Probes & Primers, Buffers, Nucleotides, and Solutions, Labeling & Detection Reagents, ELISA Reagents & Kits (Immunosorbents, Controls, Conjugates, Substrates, Sample Diluents & Wash Solutions), Other Reagents & Kits), Instruments (Rental Purchase, Outright Purchase), Software & Services), By Technology (Nucleic Acid Test (Transcription-mediated Amplification, Real-time PCR), Serology/Immunoassay (Chemiluminescent Immunoassays, Fluorescent Immunoassays, Colorimetric Immunoassays/ELISA, Rapid Tests, Western Blot Assays), Next-generation Sequencing), By End User (Blood Banks, Hospitals) and Region

Report Code: LSDB1945Author Name: S DanielPublication Date: November 2026Pages: 293
Available In:
Available format: PDFAvailable format: ExcelAvailable format: Word
KAISO Research and Consulting

Blood Screening Market Size, Share, Trends & Global Forecast 2026–2035

Publication Date: Nov 21, 2026Pages: 293
Market Size Icon
MarketSize 2025
$ 10.64Billion
Market Forecast Icon
MarketForecast 2035
$ 33.28Billion
CAGR Icon
CAGR(2026–2035)
12.08%
Largest Region Icon
LargestRegion
NorthAmerica:
Fastest Growing Region Icon
FastestGrowing Region
AsiaPacific

Blood Screening Market Overview and Definition


The Global Blood Screening Market was valued at USD 10.64 Billion in 2025, and is projected to reach USD 33.28 Billion by 2035, growing at a CAGR of 12.08% from 2026 to 2035. This strong growth trajectory is driven by expanding global blood transfusion volumes, increasing regulatory requirements for transfusion-transmitted infection screening, and the accelerating adoption of nucleic acid testing and advanced immunoassay technologies across blood banks and hospital transfusion services.


Reagents and kits represent the leading product segment, with NAT reagents and ELISA kits accounting for the highest procurement volumes. Nucleic acid testing maintains technological leadership through its superior sensitivity in the detection of HIV, hepatitis B, hepatitis C, and emerging infectious agents. North America holds the dominant regional position, while Asia-Pacific records the fastest regional growth. Blood banks and hospitals collectively form the primary end-user base for blood screening products and services globally.


Key Market Trends & Analysis


  1. The Global Blood Screening Market was valued at USD 10.64 Billion in 2025, reflecting extensive deployment of NAT and serology-based screening across global blood supply chains.
  2. The market is projected to grow at a CAGR of 12.08% from 2026 to 2035, driven by mandatory pathogen screening requirements and rising blood collection and transfusion volumes.
  3. The Global Blood Screening Market is forecast to reach USD 33.28 Billion by 2035, supported by technology upgrades across blood banking infrastructure and growing adoption of advanced screening platforms.
  4. Expanding regulatory requirements for transfusion-transmitted infection screening and rising demand for safe blood transfusions are driving investment in advanced screening technologies and broader pathogen detection panels.
  5. Reagents & Kits dominated the Product & Service segment, accounting for approximately 58% market share in 2025, supported by recurring NAT and ELISA consumable demand across blood screening facilities.
  6. Nucleic Acid Test dominated the Technology segment, accounting for approximately 52% market share in 2025, owing to its sensitivity in detecting HIV, hepatitis B, and hepatitis C during the pre-seroconversion window period.
  7. Blood Banks dominated the End User segment, accounting for approximately 64% market share in 2025, reflecting their high-throughput screening operations and substantial consumption of instruments and reagents.
  8. North America leads the Global Blood Screening Market, supported by mandatory NAT requirements, established blood banking infrastructure, high blood collection volumes, and widespread adoption of automated screening platforms.
  9. The USA accounts for approximately 74% of the North American market, driven by FDA-mandated multi-pathogen screening, extensive blood collection infrastructure, and the presence of major market participants.
  10. Grifols S.A. expanded its Procleix Panther NAT screening portfolio in April 2025, introducing additional assay targets for emerging transfusion-relevant pathogens across blood banking customers.
  11. Asia-Pacific is the fastest-growing regional market, projected to expand at a CAGR of approximately 13.6% from 2026 to 2035, driven by national blood safety programme upgrades and increasing NAT adoption.
  12. Next-generation Sequencing is the fastest-growing technology segment, projected to register a CAGR of approximately 18.4% from 2026 to 2035, supported by its potential for simultaneous detection of known and emerging pathogens.
  13. The USA Blood Screening Market was valued at USD 4.68 billion in 2025 and is projected to reach USD 14.68 billion by 2035, growing at a CAGR of 12.1%.


The blood screening market includes products, technology, and services for screening donated blood and its components for infectious diseases that may be transmitted during a blood transfusion. Products include NAT reagents, ELISA kits, enzymes, probes, primers, standards, controls and detection reagents. Technology includes renting or buying screening devices, software and other services. Technology includes nucleic acid technologies using transcription mediated amplification and real time PCR, serology / immunoassays such as chemiluminescence, fluorescence, chromogenic, rapid assays and western blots. End users include blood banks and hospital transfusion departments who ensure the safe provision of blood products.


Strategic Importance and Market Outlook


Blood screening plays an essential role in keeping our communities safe. The prevention of transmitting infections such as HIV, Hepatitis B, Hepatitis C, West Nile Virus, Zika Virus and Chagas disease through blood transfusions relies on sensitive, specific and high-throughput screening technologies. Global regulatory bodies are increasingly increasing the requirements for mandatory screening in blood. This includes increased pathogens that need to be screened for, and an increase in the minimum requirement of screening technologies from serology only to NAT/immunology.



New infectious diseases are emerging that could be transmitted using blood transfusions. This has increased the demand for flexible and quick to adapt screening technologies. From 2035 the market will benefit from further technology advances due to regulatory requirements, increased blood collection infrastructure in Asia Pacific and LAMEA, and the slow implementation of next generation sequencing in high through-put blood screening.


→In March 2025, Roche Diagnostics announced CE-IVD marking for an updated cobas blood screening assay panel incorporating enhanced sensitivity configurations for hepatitis E virus NAT detection, expanding the pathogen coverage of its cobas 6800/8800 platforms deployed across European blood banking institutions.


Recent Developments in the Blood Screening Market


  1. In January 2025, Abbott announced the regulatory clearance and commercial availability of its PRISM Next chemiluminescent immunoassay system, featuring updated assay configurations for HIV, hepatitis B surface antigen, hepatitis C, and syphilis screening. The platform delivered improved throughput and enhanced analytical sensitivity over its predecessor, targeting high-volume blood bank and hospital transfusion laboratory customers seeking to consolidate serology screening workflows onto a single automated platform across North American and European markets.


  1. In March 2025, Roche Diagnostics received CE-IVD marking for an enhanced hepatitis E virus NAT detection configuration on its cobas 6800 and cobas 8800 blood screening systems. The updated assay expanded pathogen panel coverage for European blood banking institutions addressing hepatitis E transfusion transmission risk in immunocompromised patient populations, reinforcing Roche's competitive position in the centralised NAT blood screening segment and supporting regulatory compliance requirements in multiple European member states.


  1. In April 2025, Grifols S.A. announced an expanded Procleix Panther NAT screening portfolio with new assay targets for emerging transfusion-relevant pathogens, broadening the infectious disease panel available on its Panther platform for blood banking customers. The expansion was designed to support blood centre readiness for newly identified transfusion transmission risks and to provide a single platform solution for both established and emerging pathogen NAT screening across large-volume North American and European blood collection operations.


  1. In February 2025, bioMérieux announced the commercial launch of an updated VIDAS automated immunoassay platform configuration specifically validated for blood bank serology screening applications. The configuration supported hepatitis B, hepatitis C, HIV, and HTLV screening workflows in mid-volume hospital transfusion laboratories and regional blood centres, targeting facilities that require automated immunoassay consolidation without the capital investment required for the largest high-throughput centralised screening systems.


  1. In May 2025, Siemens Healthineers announced an expanded software analytics capability for its ADVIA Centaur immunoassay blood screening platform, incorporating laboratory information system connectivity enhancements and automated quality control flagging designed to reduce manual review workload in high-volume blood bank screening environments. The upgrade addressed a growing operational priority among blood banking institutions seeking to improve laboratory efficiency and result turnaround times without replacing existing validated instrument infrastructure.


Blood Screening Market Dynamics: Drivers, Restraints, Opportunities, Challenges and Trends


Drivers: Regulatory mandates for expanded pathogen screening panels and NAT adoption drive technology investment across global blood banking infrastructure.


The most fundamental driver in the market is regulation. Nucleic acid testing is becoming a requirement in blood screening across the major markets of North America, Europe and increasingly Asia-Pacific to help eliminate the pre-seroconversion window period for HIV, Hep B and Hep C infections. As regulations are updated to require nucleic acid testing within national screening guidelines blood centers will be required to purchase new instruments, validate new reagents and enter into new contracts with manufacturers.


Blood safety regulation across the globe is increasing, with the introduction of new pathogens including West Nile Virus, Zika virus, Hepatitis E and Chagas disease requiring investment from instrument manufacturers and reagent companies. Blood safety regulators in India, China, Brazil and South East Asia are aligning their screening requirements to those internationally accepted. This has created high demand as blood banks move to NAT and immunological screens.


Restraints: High capital and operational costs of advanced NAT screening platforms constrain adoption in resource-limited blood banking environments.


Implementing nucleic acid testing requires large capital expenditure on automation instruments, dedicated laboratory space, certified reagents and trained personnel with expertise in molecular biology. The overall total cost of ownership of NAT is proving problematic for blood centres in low income countries and smaller blood banks within developed markets due to costs associated with purchasing/renting automation equipment, reagents, service contracts and quality assurance.


The complexity of implementing NAT also presents challenges. Many facilities do not have the resources in place to provide strict protocols to prevent cross contamination, store reagents at controlled temperatures, regularly undertake proficiency testing and provide specialist training. This means many smaller blood centres and hospital blood banks in emerging markets still have serology only screening processes in place, accepting the risk of transmission during the pre-seroconversion window period.


Opportunities: Next-generation sequencing adoption in blood screening creates a technically differentiated platform opportunity for comprehensive pathogen surveillance.


Next Generation Sequencing is an emerging opportunity in the blood screening market. NGS can be used to detect both existing and novel pathogens in one assay in contrast to conventional NAT/immunoassay methods where specific targets are identified. This means that blood centres will have the ability to future-proof their screening process by using NGS to detect new threats to transfusion. Research studies at major blood banks in the US and Europe are currently using NGS based metagenomic techniques to help improve blood safety. Clinical data is being generated that will support the consideration of NGS by regulators.


Companies who have already developed NGS capability (Illumina, Thermo Fisher Scientific and Roche) will be able to develop blood screening NGS assays. This is a good opportunity in the medium term due to the decreasing cost of NGS, improved automation of bioinformatics and increased interest from regulators. Blood screening applications will start within reference labs and larger central blood centres but will gradually expand.


Challenges: Assay validation requirements and platform switching barriers slow the adoption of new screening technologies in established blood banking workflows.


Due to regulatory requirements to thoroughly validate analytical and clinical performance of blood screening assays, there are significant challenges around changing platforms and introducing new technologies into a blood bank setting. Blood centres will need to ensure that their assays are able to perform on a large panel of donors from a range of geographical areas, perform alongside an existing reference method and gain regulatory clearances/approvals from national blood safety regulating bodies. This can cause long delays (2-4 years) in implementing new technologies.


Blood centres become locked into a specific platform. If they have already invested into instruments, training and LIS integration they will want to stay with their existing vendors for their reagent and assay generation. This gives major advantage to big players like Abbott, Roche and Grifols. It creates a very high entry barrier for any new players to enter the market and introduce their alternative screening platform.


Trends: Automation and laboratory consolidation are reshaping blood screening operations toward centralised, high-throughput platform deployments.


The blood screening industry is moving towards highly automated centralised labs. This means that screening is being moved to large high throughput systems. This is due to the aim of reducing costs within the healthcare system. Centralised labs reduce costs by having a higher volume of samples tested. Automated systems reduce variability between operators and reduce manual handling. Large blood banks across the USA, UK, Germany and Australia are moving to centralised systems to test donations. Therefore there is a need for the highest throughput NAT and immunoassay systems available to test large volumes of samples.


With the desire to automate reporting, compliance and donor notification systems, software and LIMS compatibility has become an important factor when choosing a platform. Manufacturers are investing in better data analysis, automated QC and integration with e-lab systems. The centralisation, automation and integration of systems are making fully integrated systems more commercially important. This therefore puts manufacturers in a stronger position if they can provide fully integrated systems.


Where Are the Biggest Opportunities in the Blood Screening Market?


  1. NAT platform adoption in emerging market national blood banking networks in Asia-Pacific, Africa, and Latin America generates large-scale instrument and reagent procurement opportunities as screening standards are upgraded.
  2. Emerging pathogen NAT assay development for West Nile virus, hepatitis E, Zika, and Chagas disease creates new test panel revenue for established blood screening platform manufacturers.
  3. Next-generation sequencing workflow development for blood safety applications represents a technically differentiated long-term commercial opportunity in reference blood banking laboratories.
  4. Reagent supply agreement consolidation under long-term platform contracts provides recurring revenue stability for manufacturers with validated high-throughput NAT and immunoassay systems.
  5. Mid-volume automated immunoassay platform development targets hospital transfusion laboratories and regional blood centres that require automation without large centralised facility investment.
  6. Software and laboratory information system integration capabilities are increasingly critical competitive differentiators as blood centres automate reporting, compliance, and quality management workflows.
  7. Rental purchase instrument models reduce upfront capital barriers for blood centres in cost-constrained healthcare systems, expanding the addressable market for premium screening platform providers.
  8. Expansion of combined NAT and serology screening bundles offers blood centres a cost-effective consolidated platform solution, reducing per-test economics and simplifying procurement relationships.
  9. Hospital transfusion laboratory blood screening automation creates incremental demand as hospitals bring screening operations in-house to reduce dependency on centralised blood centre turnaround times.
  10. Public health emergency preparedness investment, including stockpile screening reagent procurement and rapid-response NAT assay development, creates periodic high-volume government procurement opportunities for established screening manufacturers.


Blood Screening Market Segmentation Analysis


Report Attributes

Details

Market Size in 2025

USD 10.64 Billion

Market Size by 2035

USD 33.28 Billion

CAGR (2026-2035)

12.08%

Base Year

2025

Forecast Period

2026-2035

Historical Data

2022-2024

Report Scope & Coverage

Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, Analysis, Forecast Outlook

Key Segments

By Product & Service:

  1. Reagents & Kits
  2. NAT Reagents & Kits
  3. Enzymes & Polymerases
  4. Standards & Controls
  5. Probes & Primers
  6. Buffers, Nucleotides, and Solutions
  7. Labeling & Detection Reagents
  8. ELISA Reagents & Kits
  9. Immunosorbents
  10. Controls
  11. Conjugates
  12. Substrates
  13. Sample Diluents & Wash Solutions
  14. Other Reagents & Kits
  15. Instruments
  16. Rental Purchase
  17. Outright Purchase
  18. Software & Services

By Technology:

  1. Nucleic Acid Test
  2. Transcription-mediated Amplification
  3. Real-time PCR
  4. Serology/Immunoassay
  5. Chemiluminescent Immunoassays
  6. Fluorescent Immunoassays
  7. Colorimetric Immunoassays/ELISA
  8. Rapid Tests
  9. Western Blot Assays
  10. Next-generation Sequencing

By End User: Blood Banks, Hospitals

Regional Analysis/Coverage

North America (U.S., Canada, Mexico), Europe (UK, Germany, France, Spain, Italy, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South Korea, Rest of Asia-Pacific), LAMEA (Brazil, Argentina, UAE, Saudi Arabia, Africa, Rest of Latin America)

Company Profiles

Abbott, Danaher Corporation (Beckman Coulter), Becton Dickinson and Company, Bio-Rad Laboratories, Inc., Hoffman-La Roche Ltd., Grifols, S.A., Ortho-Clinical Diagnostics, Inc., Siemens Healthcare GmbH, Thermo Fisher Scientific, Inc., SOFINA s.a (bioMérieux)

Source: Kaiso Research and Consulting


Blood Screening Market Segment Analysis


  1. By Product & Service, Reagents & Kits dominated the Blood Screening Market in 2025 with approximately 58% share; Reagents & Kits is also the fastest-growing segment with a CAGR of approximately 12.9% from 2026 to 2035.


  1. By Technology, Nucleic Acid Test dominated the Blood Screening Market in 2025 with approximately 52% share; Next-generation Sequencing is the fastest-growing segment with a CAGR of approximately 18.4% from 2026 to 2035.


  1. By End User, Blood Banks dominated the Blood Screening Market in 2025 with approximately 64% share; Hospitals is the fastest-growing segment with a CAGR of approximately 13.2% from 2026 to 2035.


Dominating Segments in the Blood Screening Market


By Product & Service: Reagents and kits dominate blood screening procurement as recurring consumable demand drives sustained revenue growth across installed platform bases.


Reagents and Kits holds the largest share of the Blood Screening Market and is the fastest growing segment. It is expected to have approximately 58% of the global market share in 2025 and will grow at an approximate CAGR of 12.9% between 2026-2035. This is due to the fact that this segment is driven by a consumable. Reagents are purchased regularly as they are being used on validated instruments meaning there is a continuous stream of purchases to be made.


NAT reagents and kits hold the largest share of the overall segment due to the large amount of reagents required for every test performed using transcription mediated amplification and real time PCR platforms in centralised blood banks across North America and Europe. ELISA reagents and kits make up the second largest category of reagent consumption. They provide various elements including immunosorbents, conjugates, substrates and diluents for screening Hepatitis, HIV and Syphilis using serology based methods. These are used across both automated platforms in developed markets and manual/semi automated platforms in developing markets.


As more pathogens are being tested for mandatorily, there is more reagent kits required per donation. This increases the size of the reagent market. Lock-in effects also increase the revenue generated from reagents. Manufacturers with large amounts of validated instruments will benefit from this as re-validation costs are very high when switching between reagent suppliers.


→In January 2025, Abbott received regulatory clearance for updated PRISM Next chemiluminescent immunoassay reagent configurations for HIV, hepatitis B, hepatitis C, and syphilis screening, expanding its validated reagent kit portfolio across high-volume blood bank customers in North American and European markets.


By Technology: Nucleic acid testing sustains blood screening technology leadership while next-generation sequencing records the fastest adoption growth trajectory.


In 2025 Nucleic Acid Testing will hold approximately 52% of the global Blood Screening Market due to its mandated adoption in major blood banking markets, and for the increased sensitivity it provides in detecting transfusion transmitted pathogens. There are two main technologies used in the majority of NAT testing globally. These are transcription mediated amplification (Grifols Procleix) and Real Time PCR (Roche Cobas, and many others). Due to an inability to detect HIV, HBV and HCV using serological methods, NAT has become the gold standard test for ensuring blood is safe. Next Generation Sequencing is the fastest growing technology segment, expected to grow at a CAGR of approx 18.4% between 2026-2035.


Although NGS is currently only being used in research and reference labs, it is a highly innovative way to detect both existing and new pathogens. This is because NGS can detect all known pathogens in one test. The reduced cost of sequencing, improved automation of Bioinformatics and increasing interest from regulators to detect all pathogens means NGS is seeing increasing movement from research into feasibility studies. This also means that NGS is the most commercially relevant emerging opportunity in the market.


→In April 2025, Grifols S.A. expanded its Procleix Panther NAT screening portfolio with new assay targets for emerging transfusion-relevant pathogens, demonstrating the commercial strategy of extending established NAT platform utility to maintain technology leadership while NGS-based alternatives mature toward regulatory acceptance.


By End User: Blood banks consolidate blood screening leadership through high-throughput centralised operations while hospitals record the fastest end-user growth.


The dominant end user in this market are Blood Banks who account for around 64% of the global market in 2025. This dominance is due to blood donations being screened in dedicated Blood Bank facilities. These facilities process a large volume of donations a day which require extensive multi pathogen screening.


Major Blood Banking organisations such as the American Red Cross, NHS Blood and Transplant and national bodies throughout Europe and Asia-Pacific have high through put instruments and therefore consume the most NAT and immunoassay reagents. They are the main customer of the companies supplying blood screening platforms.


The fastest growing end user in this market is Hospitals. They are set to grow at around 13.2% CAGR between 2026-2035. This is due to transfusion laboratories within hospitals investing in automated blood screening platforms to decrease reliance on central blood centres, increase compatibility and infectious disease screening on site and to meet new regulatory requirements. Medium throughput immunoassay platforms such as the updated versions of the VIDAS from bioMérieux will target these hospitals as they will have an automation requirement but would not justify investing into a large centralised Blood Bank platform.


→In February 2025, bioMérieux launched an updated VIDAS automated immunoassay platform configuration validated for blood bank serology screening, specifically targeting mid-volume hospital transfusion laboratories and regional blood centres seeking automated immunoassay consolidation without large-scale centralised facility investment.


Regional Insights in the Blood Screening Market


Regional Analysis:


Region

Major Country

Share within Region, 2025 (%)

North America

USA

74%

Europe

Germany

24%

Asia Pacific

China

36%

Latin America

Brazil

31%


North America: North America leads the global blood screening market through mandatory NAT requirements, large blood collection volumes, and advanced transfusion safety infrastructure.


North America continues to dominate the global Blood Screening Market due to regulations by the FDA requiring nucleic acid testing on all donated blood. This is also helped by a well-established blood banking infrastructure across North America plus a high level of commercial players in the Blood Screening Market. The North America Blood Screening Market is expected to grow at a CAGR of approximately 11.4%.


A large portion of the Blood Screening Market in North America comes from the USA who account for around 74% of the market share. This is due to the large national blood collection/transfusion system. There is also a large amount of commercial players such as the American Red Cross and independent blood centres. Pathogens are constantly being added to the panel due to regulation, which means there is a constant cycle of technology investment.


The FDA has strict regulations regarding blood safety, requiring HIV-1, HIV-2, Hepatitis B, Hepatitis C, HTLV-I and II, West Nile Virus, Zika Virus and Trypanosoma cruzi to be screened in all blood units. This makes North America have one of the largest mandatory screening panels in the world. Canada also has high blood safety standards set by Health Canada. Canadian Blood Services provides a centralised system. Opportunities in this region include evaluating next generation sequencing technologies, upgrading software & lab information systems and consolidating reagents as blood centres renegotiate long term platform contracts.


→In April 2025, Grifols S.A. announced expanded Procleix Panther NAT assay panel availability for emerging pathogen targets at North American blood banking customers, reinforcing its position as the leading NAT screening platform provider within the USA and Canadian blood centre networks.


USA: The USA anchors North American blood screening leadership through mandatory multi-pathogen NAT requirements and large-scale centralised blood banking operations.


The USA Blood Screening Market was worth USD 4.68 billion in 2025 and is predicted to grow to reach USD 14.68 billion by 2035. This is an overall CAGR of 12.1% between 2026 and 2035. This represents around 74% of the North American market due to the large infrastructure within the USA for collecting blood nationally, the most comprehensive mandatory screening panel available globally for transfusion transmitted diseases and the home of many of the top players such as Abbott, Grifols and Ortho-Clinical Diagnostics.


The American Red Cross and America’s Blood Centers along with major hospital transfusion services are responsible for the highest amount of reagents and instruments being purchased globally. There is a mandated requirement to screen all units of blood for multiple pathogens using NAT and Serology. This creates a very strong demand for reagent purchases across the country.


The FDA have been very proactive with new pathogens entering the market with new screening requirements such as for the Zika Virus being implemented and continual review of new pathogens to require screening. This means there will be continual investment in technology and reagents by the blood banks in the USA. The USA is also the main market for new technologies to be developed and brought to market. New instruments, assays and NGS tests will be released first in the USA.


→In January 2025, Abbott received US regulatory clearance for its PRISM Next chemiluminescent immunoassay system with updated serology screening configurations, reinforcing its competitive position across high-volume American blood bank and hospital transfusion laboratory customers seeking automated multi-pathogen serology consolidation.


Europe: Europe advances blood screening technology adoption through stringent regulatory harmonisation and progressive expansion of mandatory pathogen panel requirements.


The Europe region is the second largest regional market. This is due to the comprehensive blood safety regulations set out by the EU, robust national blood banking services and strong adoption of NAT and immunoassay combination screens. The Blood Screening Market in Europe is forecasted to grow at a CAGR of approximately 11.1% from 2026 to 2035. Germany has the largest market share in Europe, taking up around 24% of the market. This is due to the German Red Cross blood service and DRK-Blutspendedienste, a high number of hospital transfusion labs, coupled with strong adoption of Roche and Siemens blood screening.


The EU Blood Safety Directive requires NAT and serology blood screening in member countries. However, each country requires different pathogens screened meaning there a varied mix of technologies adopted. The UK’s NHS Blood and Transplant have some of the biggest centralised screening services. France’s Établissement Français du Sang and Spain’s blood transfusion centres also screen large amounts of blood. Hepatitis E virus NAT screening is becoming more common in blood banks across Europe due to evidence of the disease being transmitted via transfusion. This is driving demand for more assays from leading NAT providers.


→In March 2025, Roche Diagnostics received CE-IVD marking for enhanced hepatitis E virus NAT detection on its cobas 6800 and cobas 8800 platforms, directly addressing growing European blood banking regulatory interest in hepatitis E transfusion transmission prevention.


Asia-Pacific: Asia-Pacific records the fastest regional blood screening growth driven by NAT adoption expansion and national blood safety programme modernisation.


The Asia-Pacific region will be the fastest growing region in the global Blood Screening Market due to large increases in blood supply, upgrading national blood safety programs to include NAT testing and significant investment from governments in improving blood banking infrastructure in China, India, Japan, South Korea and Australia. The Blood Screening Market in Asia-Pacific is expected to grow at a CAGR of around 13.6% from 2026-2035. China is the largest country in Asia-Pacific representing around 36% of the market share.


This is due to the country upgrading their blood safety program, the Chinese Red Cross blood collection network and large government investment into using NAT platforms. India are upgrading their national blood safety infrastructure. The National Blood Transfusion Council is upgrading blood screening by introducing more NAT testing in different states. Japan and South Korea have highly developed systems in place. They have a high amount of automation and high throughput NAT and chemiluminescent immunoassay platforms. Australia's Red Cross Lifeblood has full NAT and Serology screening in place and works on new pathogen testing.


→In May 2025, Siemens Healthineers announced expanded laboratory information system connectivity upgrades for its ADVIA Centaur blood screening platform, targeting Asia-Pacific blood banking customers seeking automated quality control and result reporting integration as national blood centre consolidation programmes advance.


Japan: Japan sustains advanced blood screening capabilities through technically mature national blood banking operations and consistent transfusion safety investment.


Japan has a large share of the Asia-Pacific Blood Screening Market; taking up just under 20%. The country has a technologically advanced and integrated national blood bank system run by the Japanese Red Cross Society. There is a high rate of using NAT and automated immunoassays as part of the screening of all blood donations in the country. The Pharmaceuticals and Medical Devices Agency also have stringent regulations regarding the approval of assays used for blood screening within Japan. The Blood Screening Market will grow at a CAGR of around 10.8% from 2026-2035.


The Japanese Red Cross Society has an integrated network of blood screening centres. They utilise automated high-throughput NAT and chemiluminescent immunoassays. As a result they have one of the lowest transfusion transmitted infection rates in the world. The PMDA have strict regulations around the approval of assays. This means that only highly validated tests are used.


As a result there is a stable market, however it can be demanding for those looking to enter from an international perspective. The country does play an active roll in some new research surrounding pathogen screening. Collaborations between academic bodies and blood banks are looking into new screening panels and next generation sequencing technology to meet future needs of blood safety within the Asia-Pacific region.


→In March 2025, Roche Diagnostics Japan announced the commercial availability of updated cobas blood screening assay configurations incorporating enhanced sensitivity specifications for hepatitis B virus NAT detection at Japanese Red Cross Society blood screening centres, supporting continued improvement in transfusion safety performance standards.


LAMEA: LAMEA presents significant blood screening growth opportunities as national blood safety programmes expand NAT adoption and infrastructure investment accelerates.


LAMEA is a high growth region for the Blood Screening Market, with much need in sub-Sahara African countries, progressive NAT adoption in Latin American countries, and increased healthcare expenditure in Gulf Cooperation Council countries to develop Blood Banking technologies. Over the next decade (2026-2035) the Blood Screening market will grow at a CAGR of around 12.8%. Brazil is the key country in this region, with around 31% of the total LAMEA market share. They have a national blood product programme known as Hemobras, a well-developed national blood banking infrastructure provided by HEMOBRÁS and state hemotherapy centres.


Brazil are progressing with NAT screening for HIV, Hepatitis B and Hepatitis C. Africa has the greatest growth potential long term within the region, with high rates of HIV, Hepatitis B and Hepatitis C and little blood screening infrastructure in place meaning there is a great need for screening. International health organisations are working with these countries to help.


UAE and Saudi Arabia are investing in new blood banking technologies to meet international standards. Many Latin American countries, including Argentina, Colombia and Mexico are increasing NAT usage in their national blood centres. This means new procurement opportunities for reagents and instruments for companies providing well-established blood screening technologies.


→In April 2025, Abbott announced expanded commercial partnerships with regional blood banking distributors across Latin American markets to increase availability of its PRISM immunoassay blood screening platform, supporting national blood safety programme upgrades in Brazil, Argentina, and Mexico.


How Can Stakeholders Benefit from the Blood Screening Market Report?


  1. The report offers a quantitative assessment of market segments, emerging trends, projections, and market dynamics for the period 2024 to 2035.
  2. The report presents comprehensive market research, including insights into key growth drivers, challenges, and potential opportunities.
  3. Porter's Five Forces analysis evaluates the influence of buyers and suppliers, helping stakeholders make strategic, profit-driven decisions and strengthen their supplier-buyer relationships.
  4. A detailed examination of market segmentation helps identify existing and emerging opportunities.
  5. Key countries within each region are analysed based on their revenue contributions to the overall market.
  6. The positioning of market players enables effective benchmarking and provides clarity on their current standing within the industry.
  7. The report covers regional and global market trends, major players, key segments, application areas, and strategies for market expansion.


Chapter 1 MARKET SNAPSHOT


1.1 Market Definition & Report Overview

1.2 Scope of the Study

1.3 Research Methodology

1.3.1 Research Objective

1.3.2 Supply Side Analysis

1.3.3 Demand Side Analysis

1.3.4 Forecasting Models


Chapter 2 EXECUTIVE SUMMARY


2.1 CEO/CXO Standpoint

2.2 Key Findings


Chapter 3 INDUSTRY LANDSCAPE


3.1 Trade Analysis

3.1.1 Tariff Regulations and Landscape

3.1.2 Export - Import Analysis

3.1.3 Impact of US Tariff

3.2 Key Takeaways

3.2.1 Top Investment Pockets

3.2.2 Top Winning Strategies

3.2.3 Market Indicators Analysis

3.3 Patent Analysis

3.4 Market Dynamics

3.4.1 Drivers

3.4.2 Restraint

3.4.3 Opportunity

3.4.4 Challenges

3.5 Porter’s 5 Force Model

3.5.1 Bargaining power of buyer

3.5.2 Threat of Substitutes

3.5.3 Bargaining power of supplier

3.5.4 Threat of new entrants

3.5.5 Industry rivalry (Barriers of Market Entry)

3.6 Value Chain Analysis

3.7 PESTEL Analysis

3.8 Technology Analysis

3.8.1 Key Technology Trends

3.8.2 Adjacent Technology

3.8.3 Complementary Technologies

3.9 Pricing Analysis and Trends

3.10 Market Share Analysis (2025)


Chapter 4. Global Blood Screening Market Size & Forecasts by Product & Service 2026-2035


4.1. Market Overview

4.2. Reagents & Kits

4.2.1. NAT Reagents & Kits

4.2.1.1. Current Market Trends, and Opportunities

4.2.1.2. Market Size Analysis by Region, 2026-2035

4.2.1.3. Market Share Analysis by Top Countries, 2026-2035

4.2.2. Enzymes & Polymerases

4.2.3. Standards & Controls

4.2.4. Probes & Primers

4.2.5. Buffers, Nucleotides, and Solutions

4.2.6. Labeling & Detection Reagents

4.2.7. ELISA Reagents & Kits

4.2.7.1. Immunosorbents

4.2.7.2. Controls

4.2.7.3. Conjugates

4.2.7.4. Substrates

4.2.7.5. Sample Diluents & Wash Solutions

4.2.8. Other Reagents & Kits

4.3. Instruments

4.3.1. Rental Purchase

4.3.2. Outright Purchase

4.4. Software & Services


Chapter 5. Global Blood Screening Market Size & Forecasts by Technology 2026-2035


5.1. Market Overview

5.2. Nucleic Acid Test

5.2.1. Transcription-mediated Amplification

5.2.1.1. Current Market Trends, and Opportunities

5.2.1.2. Market Size Analysis by Region, 2026-2035

5.2.1.3. Market Share Analysis by Top Countries, 2026-2035

5.2.2. Real-time PCR

5.3. Serology/Immunoassay

5.3.1. Chemiluminescent Immunoassays

5.3.2. Fluorescent Immunoassays

5.3.3. Colorimetric Immunoassays/ELISA

5.3.4. Rapid Tests

5.3.5. Western Blot Assays

5.4. Next-generation Sequencing


Chapter 6. Global Blood Screening Market Size & Forecasts by End User 2026-2035


6.1. Market Overview

6.2. Blood Banks

6.2.1. Current Market Trends, and Opportunities

6.2.2. Market Size Analysis by Region, 2026-2035

6.2.3. Market Share Analysis by Top Countries, 2026-2035

6.3. Hospitals


Chapter 7. Global Blood Screening Market Size & Forecasts by Region 2026-2035


7.1. Regional Overview 2026-2035

7.2. Top Leading and Emerging Nations

7.3. North America Blood Screening Market

7.3.1. U.S. Blood Screening Market

7.3.1.1. Product & Service breakdown size & forecasts, 2026-2035

7.3.1.2. Technology breakdown size & forecasts, 2026-2035

7.3.1.3. End User breakdown size & forecasts, 2026-2035

7.3.2. Canada

7.3.3. Mexico

7.4. Europe Blood Screening Market

7.4.1. UK Blood Screening Market

7.4.1.1. Product & Service breakdown size & forecasts, 2026-2035

7.4.1.2. Technology breakdown size & forecasts, 2026-2035

7.4.1.3. End User breakdown size & forecasts, 2026-2035

7.4.2. Germany

7.4.3. France

7.4.4. Spain

7.4.5. Italy

7.4.6. Rest of Europe

7.5. Asia Pacific Blood Screening Market

7.5.1. China Blood Screening Market

7.5.1.1. Product & Service breakdown size & forecasts, 2026-2035

7.5.1.2. Technology breakdown size & forecasts, 2026-2035

7.5.1.3. End User breakdown size & forecasts, 2026-2035

7.5.2. India

7.5.3. Japan

7.5.4. Australia

7.5.5. South Korea

7.5.6. Rest of APAC

7.6. LAMEA Blood Screening Market

7.6.1. Brazil Blood Screening Market

7.6.1.1. Product & Service breakdown size & forecasts, 2026-2035

7.6.1.2. Technology breakdown size & forecasts, 2026-2035

7.6.1.3. End User breakdown size & forecasts, 2026-2035

7.6.2. Argentina

7.6.3. UAE

7.6.4. Saudi Arabia (KSA)

7.6.5. Africa

7.6.6. Rest of LAMEA


Chapter 8. Company Profiles


8.1. Top Market Strategies

8.2. Company Profiles

8.2.1. Abbott

8.2.1.1. Company Overview

8.2.1.2. Key Executives

8.2.1.3. Company Snapshot

8.2.1.4. Financial Performance

8.2.1.5. Product/Services Portfolio

8.2.1.6. Recent Development

8.2.1.7. Market Strategies

8.2.1.8. SWOT Analysis

8.2.2. Danaher Corporation (Beckman Coulter)

8.2.2.1. Company Overview

8.2.2.2. Key Executives

8.2.2.3. Company Snapshot

8.2.2.4. Financial Performance

8.2.2.5. Product/Services Portfolio

8.2.2.6. Recent Development

8.2.2.7. Market Strategies

8.2.2.8. SWOT Analysis

8.2.3. Becton Dickinson and Company

8.2.3.1. Company Overview

8.2.3.2. Key Executives

8.2.3.3. Company Snapshot

8.2.3.4. Financial Performance

8.2.3.5. Product/Services Portfolio

8.2.3.6. Recent Development

8.2.3.7. Market Strategies

8.2.3.8. SWOT Analysis

8.2.4. Bio-Rad Laboratories, Inc.

8.2.4.1. Company Overview

8.2.4.2. Key Executives

8.2.4.3. Company Snapshot

8.2.4.4. Financial Performance

8.2.4.5. Product/Services Portfolio

8.2.4.6. Recent Development

8.2.4.7. Market Strategies

8.2.4.8. SWOT Analysis

8.2.5. Hoffman-La Roche Ltd.

8.2.5.1. Company Overview

8.2.5.2. Key Executives

8.2.5.3. Company Snapshot

8.2.5.4. Financial Performance

8.2.5.5. Product/Services Portfolio

8.2.5.6. Recent Development

8.2.5.7. Market Strategies

8.2.5.8. SWOT Analysis

8.2.6. Grifols, S.A.

8.2.6.1. Company Overview

8.2.6.2. Key Executives

8.2.6.3. Company Snapshot

8.2.6.4. Financial Performance

8.2.6.5. Product/Services Portfolio

8.2.6.6. Recent Development

8.2.6.7. Market Strategies

8.2.6.8. SWOT Analysis

8.2.7. Ortho-Clinical Diagnostics, Inc.

8.2.7.1. Company Overview

8.2.7.2. Key Executives

8.2.7.3. Company Snapshot

8.2.7.4. Financial Performance

8.2.7.5. Product/Services Portfolio

8.2.7.6. Recent Development

8.2.7.7. Market Strategies

8.2.7.8. SWOT Analysis

8.2.8. Siemens Healthcare GmbH

8.2.8.1. Company Overview

8.2.8.2. Key Executives

8.2.8.3. Company Snapshot

8.2.8.4. Financial Performance

8.2.8.5. Product/Services Portfolio

8.2.8.6. Recent Development

8.2.8.7. Market Strategies

8.2.8.8. SWOT Analysis

8.2.9. Thermo Fisher Scientific, Inc.

8.2.9.1. Company Overview

8.2.9.2. Key Executives

8.2.9.3. Company Snapshot

8.2.9.4. Financial Performance

8.2.9.5. Product/Services Portfolio

8.2.9.6. Recent Development

8.2.9.7. Market Strategies

8.2.9.8. SWOT Analysis

8.2.10. SOFINA s.a (bioM-rieux)

8.2.10.1. Company Overview

8.2.10.2. Key Executives

8.2.10.3. Company Snapshot

8.2.10.4. Financial Performance

8.2.10.5. Product/Services Portfolio

8.2.10.6. Recent Development

8.2.10.7. Market Strategies

8.2.10.8. SWOT Analysis


Research Methodology


Kaiso Research and Consulting follows an independent approach in making estimations to provide unbiased business intelligence. Our studies are not limited to secondary research alone but are built on a balanced blend of primary research, surveys, and secondary sources. This methodology enables us to develop a comprehensive 360-degree understanding of the industry and market landscape.


Supply and Demand Dynamics:


A. Supply Side Analysis:


We begin by assessing how suppliers contribute to overall market revenue growth. Our research then delves into their product portfolios, geographical reach, core focus areas, and key strategic initiatives. As most of our reports are based on a top-down approach, we begin by conducting interviews across the value chain. In the first round, we engage with manufacturers and companies, speaking with professionals from supply chain management, production, and sales. These discussions allow us to gather detailed insights into revenue generation, measured in millions or billions, segmented by type, platform, end-user, region, and other key parameters. This helps identify how companies are driving their products into mainstream markets and influencing the overall industry structure.


As the final step, we conduct a Pareto analysis to evaluate market fragmentation and identify the key players influencing industry structure. On the supply side, we evaluate how industry players contribute to overall market growth and revenue generation.


This includes an in-depth review of:


  1. Product Offerings – range, categories, and applications covered.
  2. Geographical Presence – regions of operation and market penetration.
  3. Strategic Initiatives – new product development, product launches, distribution channel strategies, and key application areas.


B. Demand Side Analysis:


Once supply dynamics are assessed, we then examine demand-side factors shaping the market. This involves mapping demand across applications, geographies, and end-user groups. On the demand side, we conduct interviews with a network of distributors from the organised market to gain a deeper understanding of demand dynamics. This analysis covers revenue generation segmented by type, platform, end-user, and region.


Each subsegment is interconnected to understand patterns in:


  1. Revenue contribution
  2. Growth rate
  3. Adoption levels


By aggregating demand from all subsegments, we estimate the magnitude of market-driving forces. Comparing supply and demand enables us to forecast how these dynamics influence future market behaviour.


Forecast Model (Proprietary Kaiso Engine):


Building on quantitative rigor, Kaiso integrates a Forecast Model that blends statistical precision with strategic scenario planning. Unlike generic projections, this model adapts dynamically to evolving market signals.


Our proprietary forecast engine incorporates the following layers:


  1. Baseline Projection: Derived using historical patterns, econometric baselines, and validated macroeconomic inputs.


  1. Scenario Forecasting: Optimistic, conservative, and base-case outlooks built with dynamic weighting of influencing variables (e.g., policy shifts, raw material volatility, supply chain disruptions).


  1. AI-Augmented Predictive Analytics: Machine learning algorithms detect emerging weak signals, nonlinear patterns, and correlation anomalies that standard models may overlook.


  1. Sector-Specific Modules: Tailored sub-models for fast-evolving industries (e.g., clean energy adoption curves, healthcare regulatory cycles, AI penetration trends).


  1. Resilience Testing: Shock modeling to evaluate market response under “black swan” or disruption scenarios such as pandemics, trade wars, or technology breakthroughs.


Deliverable outcomes of our Forecast Model:


  1. Granular projections by region, segment, and application (up to 2035)


  1. Sensitivity-rank matrices highlighting critical drivers and risks


  1. Dynamic update capability, ensuring forecasts remain current with real-time data

This ensures that our clients don’t just see where the market is heading, but also how robust that trajectory is under different conditions.


Approach & Methodology


At Kaiso Research and Consulting, we adopt an independent, data-driven approach to ensure objective and unbiased insights. Our methodology blends primary research, secondary research, and survey-based validation, giving us a 360° market perspective.


Research Phase


Description


Key Activities


Secondary Research

Gathering qualitative insights from a variety of credible sources.

Analysis of blogs, articles, presentations, interviews, annual reports, and premium databases such as Hoovers, Factiva, Bloomberg.

Primary Research Phase 1: CXO Perspective

Interviews with top-level executives to collect strategic insights on trends and market drivers.

Discussions with CEOs, CXOs, industry leaders; interpretation of executive viewpoints.

Primary Research Phase 2: Quantitative Data Generation

Data collection from key stakeholders along the value chain, segmented by supply and demand.

Step 1: Interviews with manufacturers and supply chain personnel to gauge revenue metrics.

Step 2: Interviews with distributors to assess demand-side revenues.

Primary Research Phase 3: Validation

Ground-level survey research for real-world data validation across the value chain.

Collaboration with local survey companies; engagement with manufacturers, wholesalers, retailers, and end-users.


On average, for each market:


  1. 45 primary interviews are conducted covering the entire value chain.
  2. Interviews last approximately 28 minutes each, including a mix of face-to-face and online formats.


This rigorous methodology guarantees realistic, credible, and unbiased market analysis.


Key Player Positioning


We assess key companies on two major dimensions:


Market Positioning: measured through revenue, growth rate, geographical reach, customer base, strategies implemented, and focus areas.


Competitive Strength: evaluated through product portfolio, R&D investment, innovation, new product introductions, and overall competitiveness.


Conclusion


Our comprehensive methodology enables us to deliver high-quality, objective, and actionable market intelligence. By balancing both supply and demand perspectives, Kaiso Research and Consulting has established itself as a trusted and recognised brand in the research and consulting landscape.


REPORT DETAILS

Data Point:500+

Companies Covered:15+

Tables:120+

Charts / Figures:80+

Market Indicators:220+ Analysed

Available Format:PDF and Excel Data Pack

Need a Custom Report?

Tailor this report to your exact business needs with our customization service.

WHY CHOOSE KAISO RESEARCH?

  • Trusted by 5000+ clients worldwide
  • In-depth primary & secondary research
  • Data backed by verified sources
  • Actionable insights for strategic decisions
  • Dedicated support from research experts

REPORT BENEFITS

  • Comprehensive market understanding
  • Identify growth opportunities
  • Make data-driven decisions
  • Benchmark against competitor
  • Strategic planning support
Kaiso Logo
Location IconOffice 205 N Michigan Ave, Chicago, Illinois 60601, USA
YouTubeInstagramLinkedIn

We Accept

Payment MethodPayment MethodPayment MethodPayment MethodPayment MethodPayment Method

About

  • About us
  • What We Believe
  • Our Mission
  • Blogs & News

Company

  • Privacy Policy
  • Terms & Conditions
  • GDPR Policy
  • Disclaimer
  • Return & Refund Policy
  • Delivery Formats
  • Cookie Policy

Contact Us

  • Request for Consultation
  • Contact Us
  • Career
  • How to Order
  • Become a Reseller
  • FAQs

Contact Detail

Phone icon+1 872 219 0417
Phone icon+91 91835 80078
Email icon[email protected]

Keep in touch

Sign up for emails

Services

    Syndicate Reports
    Custom Report Solutions
    Full Time Engagement Models (FTE)
    Strategic Growth Solutions
    Consulting Services

Industries

    Popular Reports

      Healthcare IT
      Consumer Electronics
      Renewable and Specialty Chemicals
      Engineering, Equipment and Machinery
      Nutraceuticals and Wellness Foods
      Green, Alternative, and Renewable Energy

      Semiconductors
      Electric and Hybrid Vehicles
      Enterprise and Consumer IT Solutions
      Commercial Aviation
      Financial Services

    © 2025 Kaiso Research and Consulting. All Rights Reserved.

    ISO 9001 : 2015

    Privacy PolicyTerms & ConditionsHow to OrderSiteMap
    +1 872 219 0417+91 91835 80078
    [email protected]
    KAISO Logo
    Services
    Dropdown
    Report Store
    Dropdown
    Consulting Services
    Dropdown
    Blogs & NewsAbout Us
    Dropdown
    Search
    Logo
    Search
    Services►
    Report Store►
    Consulting Services►
    Blogs & News
    About Us►